The global guillain-barre syndrome market size was estimated at USD 729.70 million in 2024 and is projected to reach USD 1,039.99 million by 2030, growing at a CAGR of 6.10% from 2025 to 2030. This growth is largely driven by an increasing number of GBS cases, especially in areas with a high prevalence of infectious diseases, which is anticipated to significantly boost demand for treatment and diagnostic solutions during the forecast period.

Additionally, improvements in diagnostic technologies, combined with heightened research and development (R&D) activities aimed at discovering innovative treatments, are expected to accelerate market growth further. Guillain-Barré Syndrome is a rare neurological disorder that can affect people of all ages but is most frequently diagnosed in individuals aged between 30 and 50 years. Globally, the disorder impacts about 100,000 people annually. In the United States, estimates from the Centers for Disease Control and Prevention (CDC) indicate that roughly 3,000 to 6,000 new GBS cases are diagnosed each year. A recent example highlighting regional concern occurred in January 2025, when at least 67 cases were reported in Pune, Maharashtra, prompting health authorities to closely monitor the outbreak and investigate its causes. Such localized spikes, particularly in regions prone to infectious disease outbreaks, drive up the demand for effective diagnostic and therapeutic options.

Since there is currently no definitive cure for GBS, ongoing research into immunomodulatory therapies and other novel treatment methods offers promising opportunities for market expansion. These emerging therapies not only enhance patient outcomes but also contribute to market growth by introducing new drugs, therapies, and medical technologies. Pharmaceutical and biotechnology companies that invest in GBS research are likely to gain a competitive edge, while healthcare systems will benefit from improved treatment protocols. As these innovative therapies advance through clinical trials, the market is expected to experience increased investments, gain necessary regulatory approvals, and see the commercialization of new treatment options in the near future.

Key Market Trends & Insights:

• In 2024, North America held a leading position in the global Guillain-Barré Syndrome (GBS) market, capturing a significant share of 44.24% worldwide. Within North America, the United States emerged as the dominant regional player, accounting for an impressive 69.75% of the market share in the same year.

• When analyzing the market based on product categories, the intravenous immunoglobulin (IVIG) segment stood out prominently, securing the largest revenue share at 52.35% in 2024. Similarly, when the market is segmented by type, the intravenous immunoglobulin (IVIG) segment again led the way, holding the largest revenue share of 40.85% in 2024.

• Furthermore, considering the route of administration, the parenteral segment was the most significant, capturing a dominant revenue share of 65.75% in 2024. This data highlights the key areas within the Guillain-Barré Syndrome market that are driving growth and investment, with North America and specifically the U.S., as well as IVIG products and parenteral administration methods, playing crucial roles.

Order a free sample PDF of the Guillain-Barre Syndrome Market Intelligence Study, published by Grand View Research.

Market Size & Forecast:

• 2024 Market Size: USD 729.7 Million

• 2030 Projected Market Size: USD 1,039.99 Million

• CAGR (2025-2030): 6.10%

• North America: Largest market in 2024

Key Companies & Market Share Insights:

Some of the key players actively operating in the global Guillain-Barré Syndrome (GBS) market include CSL Behring LLC, Grifols SA, F. Hoffmann-La Roche Ltd, and Takeda Pharmaceutical Company Limited. The market landscape is significantly influenced by strategic activities such as mergers, acquisitions, and partnerships among these companies. Additionally, substantial investments in research and development (R&D) are being made to address unmet medical needs and to broaden the range of available treatment options for GBS patients.

At the same time, newer and emerging companies within the GBS market are focusing on specialized and niche areas. These include developing personalized treatment approaches that cater specifically to individual patient profiles. Such personalized therapies take into account various factors like the severity of the disease, the patient’s genetic predisposition, and their unique response to treatments. Moreover, some companies are innovating in the field of drug delivery systems to enhance both the effectiveness and ease of use of therapies. For example, efforts are underway to develop oral immunoglobulins or novel methods for more efficient plasma exchange, aiming to improve patient outcomes and convenience.

Key Players

• AbbVie Inc.

• Biogen

• Cadila Pharmaceuticals

• CSL

• F. Hoffmann-La Roche Ltd.

• GSK plc

• Grifols S.A.

• LGM Pharma

• Merck & Co., Inc.

• Octapharma AG

• Pfizer Inc.

• Takeda Pharmaceutical Company Limited

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion:

The Guillain-Barré syndrome market is expected to grow steadily due to increasing incidence rates, especially in regions with frequent infectious diseases. Advances in diagnostics and ongoing research into new treatments are driving market expansion. The lack of a definitive cure encourages development of innovative therapies, while personalized treatment approaches and improved drug delivery methods are gaining focus. Overall, growing awareness and investment in research are fueling the market’s progress.